Arbutus Biopharma (ABUS) Other financing activities (2019)

Arbutus Biopharma's (ABUS) quarterly Other financing activities came in at $18.5 million in Q3 2019.

Arbutus Biopharma (ABUS) Other financing activities (2019) Analysis & Trends

Arbutus Biopharma has disclosed Other financing activities across 1 years of filings, most recently posting $18.5 million for Q3 2019.

Other financing activities for Q3 2019 came in at $18.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $18.5 million (changed N/A YoY), and the FY2019 annual result was $18.5 million, changed N/A from the prior year.
Other financing activities came in at $18.5 million for Q3 2019 at Arbutus Biopharma.
In the past five years, Other financing activities ranged from a high of $18.5 million in Q3 2019 to a low of $18.5 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Arbutus Biopharma	882.62 Mn	882.62 Mn	-

Download Data

Date	Value
Sep 30, 2019	18.55 Mn
Sep 30, 2019	18.55 Mn